Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals has signed a $30m supply agreement with RHEI Pharmaceuticals for MuGard, a ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, in China.
Subscribe to our email newsletter
As per the agreement, Access will ensure manufacturing capacity of up to a minimum of $30m of product in the licensed territories.
Access has also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals in Shenzhen, China, in an effort to leverage Jian An’s extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan.
Access will retain its existing milestone and royalty structure for the territory.
In addition, Access and RHEI have also filed a new patent application in China covering MuGard for the relief and reduction of erythema. The new application is expected to provide additional IP protection as well as the potential for a new indication for MuGard.
RHEI Pharmaceuticals CFO Sven de Backer said that Jian An’s local expertise will expedite the ongoing marketing approval process allowing the firm to begin providing patients with an effective treatment for oral mucositis.
Jian An Pharmaceuticals CEO Zhan Zhangyi said that MuGard is the right product to help Jian continue increasing its pharmaceutical market penetration in China.
Access Pharmaceuticals CEO Jeffrey Davis said that RHEI and Jain An will greatly enhance the firm’s efforts to bring MuGard to the many patients that may otherwise suffer from the debilitating side effect of anticancer treatments.